Insulin degludec: overview of a novel ultra long-acting basal insulin

Diabetes, Obesity & Metabolism
S C L GoughM Davies


All the basal insulin products currently available have suboptimal pharmacokinetic (PK) properties, with none reliably providing a reproducible and peakless pharmacodynamic (PD) effect that endures over 24 h from once-daily dosing. Insulin degludec is a novel acylated basal insulin with a unique mechanism of protracted absorption involving the formation of a depot of soluble multihexamer chains after subcutaneous injection. PK/PD studies show that insulin degludec has a very long duration of action, with a half-life exceeding 25 h. Once-daily dosing produces a steady-state profile characterized by a near-constant effect, which varies little from injection to injection in a given patient. Clinically, insulin degludec has been shown consistently to carry a lower risk of nocturnal hypoglycaemia than once-daily insulin glargine, in both basal+bolus and basal-only insulin regimens. The constancy of the steady-state profile of insulin degludec also means that day-to-day irregularities at the time of injection have relatively little PD influence, thereby offering the possibility of greater treatment flexibility for patients.


Sep 30, 1993·The New England Journal of Medicine·UNKNOWN Diabetes Control and Complications Trial Research GroupC Siebert
Sep 12, 2000·Lancet·G B Bolli, D R Owens
Jun 25, 2002·Best Practice & Research. Clinical Gastroenterology·Anders Lindholm
Jul 2, 2003·Expert Opinion on Pharmacotherapy·Vincent McAulay, Brian M Frier
Oct 28, 2003·Diabetes Care·Matthew C RiddleUNKNOWN Insulin Glargine 4002 Study Investigators
Sep 14, 2004·Pharmaceutical Research·Svend HavelundPeter Kurtzhals
Dec 24, 2005·The New England Journal of Medicine·David M NathanUNKNOWN Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study Research
Jan 5, 2006·Diabetes & Metabolism·P Kurtzhals
Apr 22, 2006·Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists·Matthew C Riddle
May 24, 2006·Archives of Medical Research·Freddy G EliaschewitzUNKNOWN HOE 901/4013 LA Study Group
Aug 2, 2007·Diabetes/metabolism Research and Reviews·J H DevriesT R Pieber
May 10, 2008·Archives of Physiology and Biochemistry·Paolo RossettiGeremia B Bolli
Apr 17, 2010·Primary Care Diabetes·Luigi MeneghiniMartin J Abrahamson
Nov 10, 2011·International Journal of Clinical Practice. Supplement·J Pickup
Jun 18, 2011·Postgraduate Medicine·Jeff Unger, Christopher Parkin

❮ Previous
Next ❯


Nov 12, 2013·Primary Care Diabetes·Kamlesh KhuntiGuy Rutten
Dec 19, 2014·Expert Opinion on Drug Delivery·Darrell Sleep
Dec 15, 2015·Canadian Journal of Diabetes·Kitty Kit Ting Cheung, Peter Alexander
Mar 19, 2016·Nature Reviews. Drug Discovery·Alexander N ZaykovRichard D DiMarchi
Jul 31, 2014·Diabetes, Obesity & Metabolism·W M Valencia, H Florez
Jul 3, 2015·Diabetology & Metabolic Syndrome·Marcos Antonio Tambascia, Freddy Goldberg Eliaschewitz
Jan 8, 2015·Therapeutic Delivery·Ukrit AngkawinitwongGareth R Williams
Nov 9, 2016·Endocrinology and Metabolism Clinics of North America·Alissa R SegalRichard S Beaser
Nov 12, 2014·Journal of Diabetes Science and Technology·Alissa R Segal, Nuha El Sayed
Jun 22, 2016·Journal of Diabetes Science and Technology·Andreas PfütznerDiethelm Tschoepe
May 13, 2017·Diabetes, Obesity & Metabolism·Nina WronkowitzJürgen Eckel
May 17, 2017·Diabetes, Obesity & Metabolism·Adrian BrownGary Frost
Oct 12, 2017·Expert Opinion on Biological Therapy·Takahisa HiroseMads Peter Hemmingsen
Nov 24, 2017·Current Medical Research and Opinion·Fernando OvalleJeffrey A Jackson
May 13, 2020·Endocrine Reviews·Irl B HirschEugene E Wright
Jul 9, 2014·Nature Reviews. Clinical Oncology·Ignacio MeleroHåkan Mellstedt
May 1, 2020·Science Translational Medicine·Ioannis AkoumianakisCharalambos Antoniades
Dec 22, 2016·The AAPS Journal·Morten Schlein
Mar 9, 2021·Frontiers in Pharmacology·Nuria ArdaizPedro Berraondo
Jan 29, 2020·Bioconjugate Chemistry·Arnab RudraRobert Langer
Sep 18, 2021·Diabetes, Obesity & Metabolism·Ravi Retnakaran, Bernard Zinman

❮ Previous
Next ❯

Related Concepts

Related Feeds

Autoimmune Diabetes & Tolerance

Patients with type I diabetes lack insulin-producing beta cells due to the loss of immunological tolerance and autoimmune disease. Discover the latest research on targeting tolerance to prevent diabetes.